Introducing Fierce Biotech's 2026 Fierce 15

On Oct. 5, 2026, Fierce Biotech released its 24th annual “Fierce 15” list, naming fifteen private companies whose science and market positioning promise to reshape drug development.

Its lead candidate, SIR2501, is an allosteric SARM1 inhibitor pursuing fast‑track status for ALS and chemotherapy‑induced neuropathy. Parallel programs include a first‑in‑class NAMPT activator for metabolic dysfunction and a brain‑penetrant RIPK1 inhibitor for inflammatory disease, bolstered by a proprietary brain‑delivery platform. Sironax’s inclusion reflects the firm’s ambition to tackle neurodegeneration, metabolism and inflammation with first‑in‑class mechanisms.

Switzerland‑Denmark joint venture ReproNovo earned its place by confronting fertility gaps on both sides of the reproductive equation. Its oral aromatase inhibitor RPN‑001 (leflutrozole) targets low sperm count and testosterone in men, while RPN‑002 (nolasiban), an oxytocin‑receptor antagonist, is being tested to lift pregnancy and live‑birth rates in assisted‑reproductive‑technology cycles and to treat adenomyosis. The company’s global trial footprint—spanning the U.S., Europe and China—underscores a strategic push to broaden the therapeutic toolbox for millions facing infertility.

“​We are honored to be recognized among this year’s Fierce 15 companies,” said Kenneth Greenberg, CEO of SonoThera, which secured a $125 million Series B in June. SonoThera’s core innovation is an ultrasound‑mediated, non‑viral gene‑delivery platform that aims to surmount the tissue‑specific barriers that have long limited genetic medicines.

Freya Biosciences, a Copenhagen‑Boston hybrid, rounds out the list with a focus on women’s immunology. Phase 1 data for FB301—a therapy designed to improve embryo‑implantation success in IVF—met all primary and secondary endpoints without serious adverse events, positioning Freya to address a deeply unmet need in reproductive health.

Yet significant uncertainties remain. It is unclear whether Sironax’s SIR2501 will secure fast‑track status beyond its current FDA request, a gatekeeper for accelerated timelines. Likewise, SonoThera’s ultrasound‑mediated delivery must prove scalable and safe in human trials before the promise of non‑viral gene therapy can be realized. These open questions will shape each firm’s trajectory and the broader perception of the Fierce 15 cohort as a bellwether for biotech’s next growth wave.